Browse Companies

The Grayscale Chainlink Trust ETF (GLNK) transitioned to an active creation/redemption model upon its NYSE Arca listing in December 2025, aligning NAV accounting with T+1/T+2 settlement cycles. The trust’s NAV and share price remain closely linked to the underlying LINK token, with market dynamics such as trading hour mismatches and ownership concentration influencing valuation. GLNK reported a net loss of $19.4 million for fiscal year 2025, reflecting operational costs amid digital asset market volatility. Index pricing is maintained by CoinDesk Indices, Inc., which regularly updates constituent platforms to ensure accurate valuation. While legal proceedings involving related entities pose no material impact currently, regulatory risks around digital asset classification persist. Investors should monitor index composition changes, authorized participant activity, and regulatory developments as key indicators of GLNK’s outlook.

Since its 2018 spin-off, KLX Energy Services Holdings (KLXE) has built a diversified oilfield services business centered on engineered solutions for unconventional wells across major U.S. basins. The company blends proprietary product innovation with over 60 geographically dispersed service sites to address complex drilling and completion demands. While revenues and operating cash flow contracted in 2025 due to lower customer activity, KLXE’s March 2025 refinancing extended maturities but introduced high-interest debt with restrictive covenants limiting capital return flexibility. Going forward, growth depends on expanding engineered solutions and navigating commodity-driven cyclicality alongside financial leverage constraints.

Atlanticus Holdings Corp has sustained strong revenue growth primarily driven by its acquisition of Mercury in 2025, which significantly expanded its credit card receivables. The company operates two main segments: Credit as a Service (CaaS), providing tailored credit card products via bank partnerships, and Auto Finance through its CAR subsidiary. It uses advanced data analytics and machine learning for risk management, focusing on less-than-prime consumers. Despite solid operational cash flows and increasing net income, Atlanticus faces risks from credit losses in a volatile economic environment and dependencies on capital markets for financing receivables. The company maintains a leveraged capital structure, emphasizing opportunistic buybacks and disciplined cash flow management to support shareholder returns.

Centurion Acquisition Corp. launched in January 2024 and raised $287.5 million through an IPO held in trust to facilitate a business combination primarily in digital technology. As a newly formed blank check company without operational revenue, it carries inherent execution risks tied to successfully identifying and closing a target deal before its June 2026 deadline. Financial results reflect net income predominantly from interest earned on trust assets, offset by operating costs related to public company compliance and due diligence. The company’s capital structure and liquidity are strong yet highly dependent on successful transaction execution within the allotted timeframe.

In the first quarter of fiscal 2026, BJ's Wholesale Club reported a 10% increase in membership fee income, signaling strong customer loyalty and recurring revenue strength. The company repurchased over $450 million in common stock under its ongoing share repurchase program, reflecting management’s confidence and capital discipline. Regional momentum, particularly in Texas, combined with supply chain capacity expansion initiatives such as a new Ohio distribution center planned for 2027, position BJ’s well for sustained growth. However, liquidity remains tight with a current ratio below 1, posing watchpoints in an intensely competitive warehouse club market.

IN8BIO, INC. leverages its proprietary DeltEx gamma-delta T cell platform to develop multiple cell therapy candidates targeting cancer and autoimmune diseases, with early clinical data suggesting promising efficacy signals. Despite progress in clinical trials, the company continues to operate at significant losses, though operating income improved by over 36% in FY2025 versus prior years. Liquidity remains a key concern with a high current ratio counterbalanced by going concern disclosures and dependency on third-party manufacturing. Regulatory and commercial hurdles compound operational risks in this complex biotech space. Key milestones to watch include advanced clinical trial readouts and successful scale-up of bio-manufacturing.

Champions Oncology, Inc. has returned to profitability in fiscal 2025, primarily driven by growth in its research services utilizing a proprietary TumorBank of approximately 1,500 PDX models. The company's integrated Datacenter and artificial intelligence-powered SaaS platform support both experimental and computational oncology research for pharmaceutical and biotech clients worldwide. Despite competitive pressures from well-resourced incumbents and open-source alternatives, Champions continues to invest in expanding its TumorBank, enhancing analytical platforms, and advancing novel drug discovery efforts in targeted therapy, immune oncology, and cell therapy. Operating cash flows have improved substantially, supporting a positive free cash flow profile as product offerings scale, though liquidity remains a key watch area going forward.

OppFi Inc. demonstrated significant financial progress in fiscal year 2025, with revenues climbing 18.6% and operating income surging over 76%, underscoring effective scaling of its consumer lending platform powered by a proprietary underwriting engine featuring a 79% auto-approval rate. Strategic platform migrations aim to enhance long-term operational scalability even as the company navigates liquidity risks linked to tight financial covenants under its revolving credit facility. Capital allocation includes a growing share repurchase program and dividends, balancing shareholder returns with growth investments. Monitoring covenant compliance, post-migration loan volume, and cash flow trends will be key for visibility into sustained performance.

The Oncology Institute, Inc. (TOI) has expanded rapidly since its inception in 2007, evolving from a regional player in community oncology to a national leader operating over 60 physician-owned clinics and managing about 2 million patients under value-based contracts. Despite top-line growth powered by population health management contracts across multiple states, the company continues to report significant operating and net losses, reflecting high costs of scaling and risk management complexities inherent in oncology care. TOI’s future growth relies on deepening value-based relationships with payors and expanding clinic capacity, but liquidity constraints and reimbursement risks pose ongoing challenges. Monitoring milestone profitability targets for 2026 and operational improvements will be critical to assessing TOI’s path toward sustainable cash flow generation.

Volato Group, Inc. continues to advance its integrated aviation platform, Vaunt, through strategic partnerships that expand its light jet fleet and initiate leasing programs. Simultaneously, it is exploring diversification into cryptocurrency mining technology. However, its latest quarterly filing highlights critical challenges including liquidity deficits, operating losses, and regulatory noncompliance risks on the NYSE American exchange. The ongoing merger with M2i Global further adds complexity to its corporate trajectory, positioning the company at a pivotal juncture where execution and funding are decisive for future progress.

ON24 Inc., a subscription-based technology provider specializing in live engagement platforms integrating AI features, saw swift revenue expansion through 2020-2021 followed by a multi-year decline amid intensified competition and shifting market preferences. The firm reported improving but still negative operating income and net losses in recent years, while making sizable share repurchases. Liquidity remains solid with a strong current ratio and positive operating cash flow, although ROE remains negative. The acquisition deal by Cvent reshapes the company's near-term outlook, raising integration risks but potentially expanding scale in a competitive environment.

Stereotaxis, Inc. specializes in computer-controlled magnetic navigation technology that precisely manipulates flexible catheter tips during cardiac ablation and other endovascular interventions. Despite advancing its product portfolio and regulatory clearances, the company has faced declining revenue and sustained operating losses. Its commercial model balances capital system sales with recurring disposables and service contracts, but lengthy sales cycles and strategic dependencies limit growth visibility. Expansion into neurovascular and peripheral vascular procedures alongside recent acquisitions offer diversification opportunities, while significant risks remain in regulatory approvals, supply chain single sourcing, and market adoption.

Founded in 2018 and evolving through strategic mergers, Opus Genetics focuses on developing gene therapies for inherited retinal diseases (IRDs) with a specialized portfolio of seven AAV-based programs. Financially, the company bears significant operating losses driven by pipeline progression but maintains robust liquidity with a current ratio above 6. Its lead candidate, OPGx-LCA5, benefits from expedited regulatory pathways while facing the inherent developmental risks typical of early-stage biotech. Limited equity financing capacity and ongoing patent litigation underscore notable operational risks. Observers should monitor clinical milestones, regulatory developments, and manufacturing scale-up as indicators of future progress.

GRAIL, Inc. has established a substantial clinical evidence base for its Galleri multi-cancer early detection (MCED) blood test through large-scale studies such as PATHFINDER 2 and the NHS-Galleri Trial. The company submitted its PMA application to the FDA in early 2026, marking a critical regulatory inflection point that could drive broader market adoption. While operational losses narrowed substantially in 2025, driven by scaling efficiencies, reimbursement uncertainty and regulatory risks remain significant challenges. GRAIL’s capital position is solid with strong liquidity supported by equity infusions from Samsung, though it has yet to generate positive cash flows or returns.

In Q1 2026, Omega Flex reported steady sales, a dip in operating profit largely due to higher raw-material costs, and maintained robust liquidity with nearly $50 million in cash. The company’s flexible metal hose products, notably TracPipe® and MediTrac®, continue to leverage patented manufacturing processes that enable faster installation times—key to customer adoption in construction and healthcare markets. While dependence on a concentrated product line and distributor network presents risks, Omega Flex's intellectual property portfolio and established channel relationships underpin its competitive positioning. Investors should watch for developments in raw material price management, legal claims outcomes, and any updates on market expansion efforts.

Acacia Research Corporation has historically exhibited sharp fluctuations in its income statements, reflective of the challenges inherent in integrating diverse acquisitions and managing costly intellectual property litigations. However, recent fiscal year 2025 results highlight a significant improvement in operating income, net income, and operating cash flow, underscoring renewed operational resilience. This turnaround is underpinned by the company's disciplined acquisition strategy, long-term ownership philosophy, and its strategic partnership with Starboard Value, LP, which collectively anchor its ability to unlock value and navigate patent enforcement complexities. Despite ongoing risks in patent litigation and integration hurdles, Acacia's robust liquidity position and improved capital structure provide a foundation for measured growth going forward.

Korro Bio, Inc. reported revenue growth to $6.4 million in 2025 alongside deepening operating losses of approximately $122 million, reflective of its development-stage status investing heavily in R&D. The company's proprietary RNA editing platform, OPERA®, remains central to its strategy amid typical biotech risks. A recent $85 million PIPE financing extends Korro's cash runway into late 2028, supporting ongoing clinical development and operational needs. Management's November 2025 workforce reduction aims to optimize resources while maintaining focus on advancing pipeline candidates.

Inflection Point Acquisition Corp. IV completed its business combination with Merlin Labs in early 2026, transforming from a SPAC shell into a specialized aerospace and defense technology company focused on assured autonomous flight systems. The latest 10-Q discloses material weaknesses in internal controls and ongoing net losses typical of an early-stage tech firm, alongside strong liquidity supported by PIPE financing. This shift positions the company within a high-barrier aerospace defense sector characterized by complex regulatory requirements and long sales cycles, with growth driven by technological innovation and strategic partnerships such as the one with GE Aerospace. Key risks include integration execution, control remediation, and competitive pressure inherent to the defense industry.

In FY2025, GoPro faced a marked 19% revenue contraction and operational losses driven by shrinking hardware shipments amid intensifying competition. The company’s flagship HERO13 Black leverages its GP2 processor and advanced stabilization, with development underway on an AI-powered GP3 SoC to differentiate in a commoditized market. Recurring subscription revenue of $106 million remains stable, providing steady cash flow amid hardware volatility. Liquidity pressures and covenant challenges have been managed through credit facility amendments and convertible debenture issuance, while no share repurchases occurred as cash conservation remains key. Market headwinds from smartphone encroachment and supplier concentration pose ongoing risks. Future growth hinges on successful product launches, subscription expansion, and managing operational efficiencies.

Allogene Therapeutics advances its proprietary allogeneic CAR T platform targeting oncology and autoimmune diseases, with pivotal readouts expected in Q2 2026. The ALPHA3 Phase 2 trial for cema-cel in first-line large B-cell lymphoma represents a potential inflection point, while other pipeline candidates explore autoimmune and solid tumor indications. The company remains in a developmental stage with ongoing net losses but improving financial metrics, supported by its in-house Cell Forge 1 manufacturing facility. Investors should monitor clinical safety signals, regulatory developments, and capital allocation as the company approaches key milestones.

Open Lending Corp has established a data-driven foundation through its Lenders Protection Platform (LPP) to serve near-prime and non-prime auto loan markets, facilitating over one million loans totaling nearly $28 billion in originations by 2025. The recent introduction of ApexOne Auto expands its reach into prime borrowers with a risk-based pricing model sans default insurance. Fiscal year 2025 saw a marked improvement in operating results, narrowing losses significantly amid deteriorated cash flows, underscoring operational headwinds. Key risks include customer concentration, reliance on insurance partners, ongoing regulatory scrutiny, and cybersecurity threats that could constrain growth. Monitoring ApexOne Auto’s lender adoption, insurer relationships, and regulatory developments will be critical to assessing Open Lending’s future trajectory.

Whitehawk Therapeutics has strategically transformed its portfolio by divesting FYARRO to concentrate on a trio of next-generation antibody drug conjugates built on the CPT113 linker-payload platform. The company’s Phase 1 clinical trials for HWK-007 and HWK-016 are actively recruiting with data anticipated in early 2027, while an IND submission for HWK-206 is planned for mid-2026. Financially, escalating operating losses reflect growing R&D investments characteristic of early-stage biopharma, balanced against a solid liquidity position supported by a high current ratio. Operational reliance on external partners underscores both efficiency and risk as Whitehawk navigates complex development and regulatory pathways.

OnKure Therapeutics employs a proprietary platform to selectively inhibit the PI3K alpha H1047R mutation, differentiating itself from broader non-selective inhibitors currently available. Despite this scientific innovation, the company faces operational headwinds including significant operating losses, a limited cash runway extending into late 2026, and post-merger organizational integration risks. Its Phase 1 PIKture-01 trial encompasses monotherapy and combination regimens in advanced breast cancer subtypes, positioning OKI-219 as a potential backbone therapy within mutation-driven oncology. Regulatory uncertainty and competitive pressures among PI3K inhibitors remain key challenges as OnKure endeavors to transition from clinical development towards commercialization.

In 2025, Citizens, Inc. reported a 13.5% revenue increase and more than doubled net income compared to the prior year, driven by growth in international whole life sales and expanded domestic product initiatives. The company faces liquidity challenges linked to matured endowment policies while benefiting from higher investment income amid rising interest rates. Strategic technology investments and a refined segment reorganization aim to enhance underwriting efficiency and distribution in targeted markets. Despite inflationary pressures and regulatory complexities, Citizens maintains strong capital resources with no debt and a stable equity base.

Erasca, Inc. pursues a modality-agnostic strategy targeting the RAS/MAPK pathway in cancers through its clinical-stage pipeline. The company’s two lead candidates, ERAS-0015 and ERAS-4001, are in Phase 1 studies supported by exclusive licensing agreements, notably with Joyo expanding territorial rights in early 2026. Despite consistent operating losses driven by R&D investments, Erasca’s financial position remains strong with significant cash reserves. Future growth hinges on clinical data readouts, execution of combination therapy strategies, and navigating a competitive landscape alongside regulatory hurdles typical of oncology drug development.

MariMed Inc. transitioned from an advisory firm to a multi-state vertically integrated cannabis operator with 33 licenses across six states, generating revenue growth averaging 11.6% through 2020. Its portfolio of proprietary brands underpins wholesale and retail expansion via its Thrive™ dispensaries, contributing to market differentiation amid fierce competition. However, persistent federal Schedule I classification imposes tax penalties and legal uncertainty, which alongside rising operating losses despite strong cash flow, tempers near-term profitability. The company’s capital deployment shows prudence with sharply reduced capex and robust operating cash flow supporting liquidity but no shareholder returns yet. Rescheduling efforts and licensing dynamics will be pivotal for future growth trajectories.

ACNB Corporation, rooted as a community bank since 1857 in Gettysburg, Pennsylvania, underwent a transformational expansion by acquiring Traditions Bancorp in early 2025. This acquisition enhanced its branch network, introduced mortgage operations via Traditions Mortgage, and broadened service offerings to include wealth management and insurance licensed in 46 states. The company's 2025 financials reflect a significant revenue leap driven by acquisition and organic growth, supporting increased dividends and share repurchases. With assets surpassing $3.2 billion and a diversified loan portfolio across multiple sectors in its core regional market, ACNB balances growth prospects with the challenges of integration, credit quality, and regulatory changes.

KORU Medical Systems has demonstrated robust top-line growth of 22.2% in 2025, driven by its FREEDOM System platform targeting immunoglobulin therapies for PIDD and CIDP. Despite improved operating margins with a 53.9% reduction in operating losses, the company remains unprofitable at the net income level and navigates challenges from single-source suppliers and distributor concentration risks. Regulatory demands and ongoing R&D investment underscore cautious optimism about future market expansion amid operational constraints.

Runway Growth Finance Corp. experienced a pronounced decline in net income in 2025 compared to the prior year, primarily due to yield pressure on its senior secured loan portfolio. The company maintains a sizable $927 million investment portfolio focused on high-growth sectors with a dollar-weighted loan yield of 14.6%, down slightly from previous years. Operating cash flow surged substantially, reflecting strong collections and portfolio management, while capital allocation prioritized steady dividend payments alongside sizable common stock repurchases. Key risks remain credit quality in speculative debt investments and interest rate sensitivity, but the firm’s deep industry expertise and BC Partners affiliation support competitive positioning.

Lisata Therapeutics remains focused on advancing its oncology-focused clinical pipeline, highlighted by the lead candidate certepetide, despite operating losses and financial burn. The company is currently under a definitive merger agreement with Kuva Labs Inc., which provides near-term transactional uncertainty and complexity around timing and financing of the tender offer. With $16 million in cash at year-end 2025 and no significant debt, Lisata’s runway supports ongoing operations as it pursues key regulatory milestones embedded in contingent value rights linked to the merger. The clinical-stage profile, specialized management expertise, and strategic collaboration potential frame Lisata’s positioning amid inherent biotech development risks.

Bolt Biotherapeutics reported first-quarter 2026 results marked by ongoing clinical trial refinements for lead candidate BDC-4182, including introducing a step-up dosing regimen that delays initial data readouts to Q3 2026. The company continues to manage its cash burn by implementing a significant workforce reduction completed by the end of 2025, aiming to preserve capital into 2027. While Bolt’s proprietary Boltbody™ ISAC platform distinguishes its immuno-oncology pipeline, operational progress and liquidity remain tightly linked to clinical milestones and prudent cost control.

Acurx Pharmaceuticals, engaged in pioneering Gram-positive targeted antibiotics through inhibition of DNA polymerase IIIC, has improved its financial performance with a 43.5% year-over-year net loss reduction in 2025. The company's lead candidate, ibezapolstat, is progressing in Phase 3 clinical trials targeting Clostridioides difficile infection (CDI) and recurrent CDI, with regulatory feedback including EMA pediatric guidance. Despite this clinical momentum, Acurx faces liquidity risks requiring additional capital amid ongoing operating losses and negative cash flows. Upcoming clinical data readouts and financing efforts will be pivotal for its runway and market prospects.

Resolute Holdings Management, Inc. experienced an extraordinary leap in operating income in 2025 driven by its recurring fee agreement with CompoSecure Holdings. However, net losses remain stubbornly negative due to underlying expenses and non-operating costs. The company’s robust operating cash flows highlight potential for cash generation even as governance complexities and customer concentration pose risks. Monitoring operational execution, capital allocation, and management continuity will be critical to assessing future value creation.

In 2025, CoastalSouth Bancshares, Inc. delivered strong financial results driven by a 12.9% increase in gross loans, supporting enhanced net interest income alongside effective use of interest rate derivatives to manage risk. The company’s loan portfolio growth was primarily fueled by commercial and retail lending segments underpinned by rigorous credit approval standards. CoastalSouth maintained capital adequacy ratios well above regulatory minimums, supported diverse liquidity sources, and sustained dividends without share buybacks. Looking ahead, loan demand remains a key growth lever amid interest rate volatility and evolving credit risks tied to economic conditions.

TerrAscend Corp. demonstrated a marked improvement in operating income for fiscal 2025, shifting from substantial operating losses in prior years. Despite this, the company remains challenged by significant net losses, largely driven by non-operating expenses and persistent federal tax burdens under Section 280E. Its vertically integrated presence across multiple U.S. states and Canada, combined with premium brand licensing partnerships, underpin its growth prospects, but regulatory uncertainty and capital structure risks persist. Cash flow generation improved, enabling modest share repurchases while capex spending remains controlled amid ongoing debt obligations.

In its 10-Q filing for Q1 2026, Liquidmetal Technologies reported steady progress on its Hangzhou joint venture manufacturing facility, approaching full operational capability within the year. Despite these advancements, commercial production volumes remain limited, contributing to ongoing operating losses driven by elevated R&D and administrative expenses. The company's proprietary bulk amorphous alloys offer unique material properties attractive across several industries, but commercialization remains nascent with long sales lead times and supply chain concentration risks. Going forward, growth hinges on scaled manufacturing ramp-up, licensing deal expansions, and overcoming geopolitical and regulatory uncertainties tied to Chinese operations.